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Abstract
Background: The importation of malaria to non-endemic countries remains a major cause of travel-related
morbidity and a leading cause of travel-related hospitalizations. Currently they are three priority medications for
malaria prophylaxis to West Africa: mefloquine, atovaquone/proguanil and doxycycline. We investigate the cost
effectiveness of a partial reimbursement of the cheapest effective malaria chemoprophylaxis (mefloquine) for
travellers to high risk areas of malaria transmission compared with the current situation of no reimbursement.
Methods: This study is a cost-effectiveness analysis based on malaria cases imported from West Africa to
Switzerland from the perspective of the Swiss health system. We used a decision tree model and made a literature
research on the components of travel related malaria. The main outcome measure was the cost effectiveness of
malaria chemoprophylaxis reimbursement based on malaria and deaths averted.
Results: Using a program where travellers would be reimbursed for 80% of the cost of the cheapest malaria
chemoprophylaxis is dominant (i.e. cost saving and more effective than the current situation) using the assumption
that currently 68.7% of travellers to West Africa use malaria chemoprophylaxis. If the current usage of malaria
chemoprophylaxis would be higher, 82.4%, the incremental cost per malaria case averted is € 2’302. The
incremental cost of malaria death averted is € 191’833.
The most important factors influencing the model were: the proportion of travellers using malaria chemoprophy-
laxis, the probability of contracting malaria without malaria chemoprophylaxis, the cost of the mefloquine regimen,
the decrease in the number of travellers without malaria chemoprophylaxis in the reimbursement strategy.
Conclusions: This study suggests that a reimbursement of 80% of the cost of the cheapest effective malaria
chemoprophylaxis (mefloquine) for travellers from Switzerland to West Africa is highly effective in terms of malaria
cases averted and is cost effective to the Swiss health system. These data are relevant to discussions about the
cost effectiveness of malaria chemoprophylaxis reimbursement for vulnerable groups such as those visiting friends
and relatives who have the highest risk of malaria, who are least likely to use chemoprophylaxis.
Background
The importation of malaria to non-endemic countries
remains a major cause of travel-related morbidity [1]
and the leading cause of travel-related hospitalizations
[2,3]. Over the last years the number of imported
malaria decreased slightly in Switzerland and the UK
but the proportion of Plasmodium falciparum, which is
imported mainly from Sub-Saharan Africa and poten-
tially fatal with a case fatality rate of 1.2% [1,4],
increased [5,6].
Increased global mobility and ease of travel as well as
the growing number of immigrants from malaria ende-
mic countries have contributed to the importation of
malaria in Europe. The immigrants from malaria ende-
mic countries constitute a special risk group with high
levels of malaria importation because often their status
and financial circumstances hinder access to malaria
chemoprophylaxis when they will visit their home coun-
try [7]. About half of the malaria patients treated in
Switzerland have a foreign nationality [6]. West Africa is
among the endemic regions with the highest estimated
attack rates of malaria among travellers [5]. The Swiss
Federal Office of Public Health (FOPH) reported an
annual average of 112 malaria cases imported from
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West Africa for the years 2005 to 2008 [8]. This consti-
tutes 60% of all reported malaria cases in Switzerland.
Malaria preventive measures include risk awareness,
avoidance of mosquito bites and use of chemoprophy-
laxis. The current priority chemoprophylaxis regimens
for Sub Saharan Africa are mefloquine, atovaquone/pro-
guanil and doxycycline. As in many other Western
countries, the Swiss public health system does not reim-
burse travellers for any of the recommended prophylac-
tic agents. All of these anti-malaria medications have a
similar prophylactic effectiveness although they vary in
their adverse event profile and contraindications and
also in cost [9]. The burden of the imported malaria
cases in Switzerland is significant with an average of 307
imported cases and one to two deaths per year for the
time period 1988 to 2002 [4]. Treatment and productiv-
ity losses are borne by the Swiss health system.
The aim of this study is to evaluate the cost-effective-
ness of at least partial reimbursement of the cheapest
drug for chemoprophylaxis compared with the current
practice of no reimbursement for travellers medically
insured in Switzerland, who visit West Africa. Partial
reimbursement (80%) was chosen on the basis of
prior analyses and the assumption that reimbursement
will increase the use of (recourse to) malaria
chemoprophylaxis.
Methods
Study design
This study is a cost-effectiveness analysis based on
malaria cases imported from West Africa to Switzerland
and was done from the perspective of the Swiss health
system. Our work did not require ethics committee
clearance because we used available published data on
malaria risk and malaria associated costs. No human
subjects were recruited for the analysis. West Africa was
defined by OECD-definition as Benin, Burkina Faso,
Cameroon, Chad, Ivory Cost, Ghana, Guinea, Guinea-
Bissau, Gambia, Mali, Mauritania, Niger, Nigeria,
Liberia, Senegal, Sierra Leone, Togo [10]. Cape Verde
was excluded because it is not a malaria risk area.
A decision tree model (as shown in Figure 1) was
developed using TreeAge Pro 2009 (TreeAge Software,
Williamstown WA). We estimated the impact of an 80%
reimbursement for the cheapest malaria chemoprophy-
laxis regimen or a voucher for the equivalent sum of
money (”80% reimbursement strategy” label in tables). In
the model we compared that strategy to the situation of
no reimbursement, which is the current situation in
Switzerland (”current situation of no reimbursement“
label in tables). We calculated the cost for malaria che-
moprophylaxis for a two week stay in West Africa
(Table 1). So, in the proposed 80% reimbursement strat-
egy every traveller who is prescribed malaria
chemoprophylaxis would get a discount of € 17.77 (i.e.
80% of € 22.21 for mefloquine as Mephaquin®).
Travellers were divided in two theoretical groups: 1)
those who didn’t take any chemoprophylaxis and 2)
those who used chemoprophylaxis. The chemoprophy-
laxis users were divided between the three recom-
mended regimens mefloquine, atovaquone/proguanil
and doxycycline. The decision tree takes adverse events
into account. The traveller may experience adverse
events (side effects) leading to withdrawal, or may
experience adverse events without withdrawal or may
not experience adverse events from the malaria chemo-
prophylaxis. At the end, the probability of contracting
malaria is reduced (or not) by the prophylactic effective-
ness of the chosen malaria chemoprophylaxis regimen.
The probability of contracting malaria for withdrawals
was estimated to be equivalent to those travellers who
didn’t use malaria chemoprophylaxis.
The 80% reimbursement strategy presents the same
decision tree as the current situation of no reimburse-
ment but differs on two points: the probability of
recourse to malaria chemoprophylaxis and the respective
cost of 80% of the price for mefloquine.
The value to compare the two situations was deter-
mined by calculating the cost and the health outcomes.
The main outcome measure is given as incremental
cost-effectiveness ratio (ICER) in terms of incremental
cost per averted malaria case. Other outcome measures
included the number of malaria cases, deaths and
averted malaria cases for the reimbursement strategy,
the average cost of malaria and associated chemopro-
phylaxis and the probability of contracting malaria per
journey to West Africa.
Input data
The estimates of variables used in the model were prob-
abilities and medical costs stemming from a review of
the literature and are summarized in Table 2.
Estimates on probabilities
Recourse to malaria chemoprophylaxis
Three different scenarios regarding the current recourse
to malaria chemoprophylaxis for travellers to West
Africa were analysed. We used 55% as the current prob-
ability of recourse to malaria chemoprophylaxis based
on data from Pistone et al. [11] using studies of French
residents [11-15]. The other two scenarios are con-
ducted with an estimation of recourse to malaria che-
moprophylaxis of 68.7% and a high estimation of 82.4%
stemming from the data of the European airport study
[12]. We estimated the increase in use of malaria che-
moprophylaxis in the 80% reimbursement strategy to be
80.6%, 86.5%, and 92.5% using the methods of Pistone
et al. for their 65% reimbursement strategy,. Their
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assumption stems from the result of the, ‘enqûete santé
protection sociale’, ESPS (French healthcare and insur-
ance survey), in 2004 [16]. Applied to our study, the
introduction of the 80% reimbursement strategy would
lead to an estimated 57% decrease in travellers from
Switzerland to West Africa without a malaria chemo-
prophylaxis. Thus the calculation for the scenario of
68.7% usage of chemoprophylatic regimens, with 31.3%
not taking malaria chemoprophylaxis would be as fol-
lows: 31.3% * (100% - 57%) = 13.5%. This means: the
use of malaria chemoprophylaxis in the 80% reimburse-
ment strategy would be 86.5% (100%-13.5%) compared
to no reimbursement with 68.7% usage.
Distribution of recourse to the different recommended
malaria chemoprophylaxis regimens
The distribution of use of the chemoprophylactic medi-
cations (Table 1) was evaluated from 644 travellers at
the Swiss Tropical Institute (STI) in Basel. The recom-
mended agents for West Africa are mefloquine, atova-
quone/proguanil or doxycycline. For our calculations we
used the least expensive drug in the Swiss drug compen-
dium ie mefloquine as Mephaquin® [17].
The probability of contracting malaria in West Africa
without malaria chemoprophylaxis
We estimated the average length of stay for travellers to
West Africa to be 14 days. Depending on this travel
Figure 1 Decision tree modelled to estimate cost and effectiveness of an 80% reimbursement of the cheapest malaria
chemoprophylaxis regimen for travellers from Switzerland to West Africa compared to the current situation of no reimbursement. The
[+] signals the same tree as above in the figure.
Table 1 The pattern of use of malaria chemoprophylaxis in Switzerland and the cost for the traveller of each option
for a two week stay
Malaria
chemoprophylaxis
Distribution of recourse to
malaria chemoprophylaxis
(based on records from
the Swiss Tropical
Institute, Basel)
Cost of malaria chemoprophylaxis for a two
week stay in the current situation of no
reimbursement
Cost of malaria chemoprophylaxis for a
two week stay in the 80%
reimbursement strategy
Mefloquine:
Mephaquin® 8 tb
box for € 22.21
55.4% € 22.21
(maximal protection 21 days)
€ 4.20
Atovaquone/
proguanil: Malarone®
12 tb box for €
41.88
40.7% € 83.75
(maximal 15 protection days)
€ 65.99
Doxycycline:
Supracyclin®
20 tb or 10 tb box
for € 11.91 or € 6.40
3.9% € 30.23
(maximal protection 20 days)
€ 12.47
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duration we estimate that the probability of contracting
malaria in West Africa without malaria chemoprophy-
laxis would be 2.4% per two week of stay based on data
from Steffen et al. [7,11,18].
The probabilities of severe adverse events and withdrawals
We used the study from Schlagenhauf et al. for the
probabilities of severe adverse events and withdrawals
[9]. Severe adverse events were defined as events
requiring medical advice. Serious adverse events that
require admission to hospital are extremely rare. The
majority of the adverse events were of neuropsychologi-
cal or gastrointestinal nature. We assumed that the
probability of contracting malaria for the ‘withdrawals’ is
the same as for those who do not take malaria chemo-
prophylaxis and for travellers with adverse events is the
same as without adverse events.
Table 2 Estimates used to determine parameters for the decision tree model*
Definition of probabilities Estimates (likliest,
95% CI)
Date of
data
References
Current probability of recourse to malaria chemoprophylaxis in
current situation of no reimbursement
0.687/0.55/0.824 2002-2003 [12-15]
Probability of recourse to malaria chemoprophylaxis in the 80%
reimbursement strategy
0.865/0.806/0.925 - [11,16]
Probability of recourse to mefloquine 0.554 2007 Personal evaluation at the STI1
Probability of recourse to atovaquone/proguanil 0.407 2007 Personal evaluation at the STI1
Probability of recourse to doxycycline 0.039 2007 Personal evaluation at the STI1
Probability of adverse events due to mefloquine leading to
withdrawal
0.04 (0.01-0.08) 1998-2001 [9]
Probability of adverse events due to atovaquone/proguanil
leading to withdrawal
0.02 (0.00-0.04) 1998-2001 [9]
Probability of adverse events due to doxycyline leading to
withdrawal
0.03 (0.00-0.06) 1998-2001 [9]
Probability of severe adverse events due to mefloquine without
withdrawal
0.11 (0.06-0.15) 1998-2001 [9]
Probability of severe adverse events due to atovaquone/
proguanil without withdrawal
0.07 (0.02-0.11) 1998-2001 [9]
Probability of severe adverse events due to doxycyline without
withdrawal
0.06 (0.02-0.10) 1998-2001 [9]
Probability of contracting malaria without malaria
chemoprophylaxis
0.0242 (Varied ± 30%:
0.017 - 0.0314)
- [18]
Prophylactic effectiveness of mefloquine 0.945 (0.84-0.981) 1993-1995 [19]
Prophylactic effectiveness of atovaquone/proguanil 0.958 (0.915-0.975) Metaanalysis
2007
[20]
Prophylactic effectiveness of doxycyline 0.926 (0799-0.975) 1995 [21]
Rate of hospitalisation of the imported malaria cases in
Switzerland
0.63 2003-2006 Personal evaluation with data from FOPH2
and SFSO3
Medical cost variables Estimates (likliest) Date of
data
References
Direct cost of mefloquine (Mephaquin®) for two weeks in 80%
reimbursement strategy
€ 17.77 2008 [17]
Cost to treat adverse events € 37.59 2008 Personal evaluation with TARMED4 and
Swiss drug compendium[17]
Direct cost of hospitalisation due to a malaria case € 4763 2004-2005 Personal communication (SFSO)
Direct cost of ambulant treatment due to a malaria case € 368 2008 Personal communication (STI)
Average indirect cost of sick leave due to a malaria case € 2123 1996-2004 Personal communication (SUVA5)
*using the template created by Pistone[11]
1 Swiss Tropical Institute
2 Federal Office of Public Health (FOPH)
3 Federal Statistical Office (SFSO)
4 Swiss TARMED
5 Swiss accident insurance funds
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The effectiveness of malaria chemoprophylactic regimens
The estimates of the prophylactic effectiveness are based
on a review of literature on travel medicine malaria stu-
dies [19-21].
Estimates on costs
The costs are given in Euro (€) and were converted
Swiss Francs (CHF) to Euro (€) in 2009: 1 Swiss Franc
(CHF) = 0.660 Euro (€) = 0.575 British Pound (£) =
0.936 US Dollar ($).
The cost for the malaria chemoprophylactic regimens
The figures on the cost for malaria chemoprophylaxis in
Table 1 are from the official Swiss drug compendium
2008 [17]. The price for malaria chemoprophylaxis was
calculated for an adult person staying a minimum of 14
days in West Africa.
The cost to treat severe adverse events
We estimated that a person with severe adverse events
needed a ten minute consultation at the physician and a
prescription for drug against nausea and vomiting plus
one follow up visit of ten minutes. We used for our cal-
culation the price for a package of Torecan® (thiethyl-
perazine). On the basis of the medical costs system in
Switzerland, TARMED, and the ‘Swiss compendium of
drug information’ we estimated the cost for treatment of
severe adverse events at € 37.59.
The cost to treat a malaria case
The estimation of € 4’763 for the direct cost of a hospi-
talized malaria tropical case stems from unpublished
data of the ‘Swiss Federal Statistical Office’ (SFSO),
http://www.bfs.admin.ch/. The Swiss Tropical Institute
estimated that an average ambulant malaria treatment
including two physician consultations, hematology and
malaria parasite laboratory confirmation plus a treat-
ment course of Riamet® (artemether/lumefantrine) to be
€ 368. The rate of hospitalized malaria patients was
evaluated from reported cases in Swiss Federal Office of
Public Health (FOPH) and the SFSO. Thus, the average
treatment cost of a malaria case (based on both hospita-
lised and ambulatory cases) was calculated to be
€ 3’137. The average indirect cost of sick leave due to a
malaria case (days of work loss) of hospitalized and
ambulant treated patients, are calculated on the basis of
unpublished data from the Swiss Accident Insurance
Fund, SUVA, and are estimated to be € 2’123 [22].
Analysis
The results are presented as incremental cost effective-
ness ratio (ICER) in terms of cost per averted malaria
case using an 80% reimbursement of the cheapest
malaria chemoprophylaxis compared with the current
situation where there is no reimbursement for malaria
prophylaxis. ICER is calculated by dividing the incre-
mental cost of the reimbursement strategy by the
savings gained in the malaria cases. Using data from the
Swiss Federal Statistical Office (SFSO) we estimated the
annual number of Swiss travellers to West Africa to be
70’000 [23]. The estimation on the annual cost and
effects (number of malaria cases) was conducted with
the given number of travellers from Switzerland to West
Africa. Costs and benefits were not discounted given the
evaluation of malaria chemoprophylactic prevention and
treatment would occur within a year.
To test for the precision and robustness of the model-
results, deterministic sensitivity analyses were performed.
For the one way sensitivity analysis, all model parameters
were assigned a uniform probability distribution where
possible, allowing ± 30% variability around the baseline.
The variables on efficacy and probability of drop out,
adverse events and no adverse events of malaria chemo-
prophylactic regimens were varied in their confidence
interval. Furthermore, uncertainties around the result of
the base-case were assessed in a probabilistic sensitivity
analysis by using 10,000 sets of parameter values which
are randomly sampled from a beta-distribution reflecting
the ranges of variations given in Table 2[24].
Results
Cost and effect of the current situation and the 80%
reimbursement strategy
The results are shown in Table 3 for the situation of
recourse to malaria chemoprophylaxis of 55%, 68.7%
and 82.4%. The absolute results calculated for 70’000
travellers to West Africa are presented in Table 4. The
80% reimbursement strategy leads in all situations to a
significantly lower probability of contracting malaria per
traveller and also to significantly lower costs per travel-
ler in the situation of 55% and 68.7% recourse than in
the current situation of no reimbursement. Only in the
82.4% recourse situation the cost would be higher in the
80% reimbursement strategy. Assuming current use of
malaria chemoprophylaxis at 55% the reduction in
malaria cases is 47% with an 22% decrease of cost
(€ 65.45 to € 50.94per traveller); for a 68.7% recourse
the reduction of malaria cases is 45% with a 9% reduc-
tion of cost (€ 50.05 to € 45.36per traveller); for a 82.4%
recourse the reduction of malaria cases is 38% with 9%
higher costs (€ 36.64 to € 39.78 per traveller).
In a scenario with 68.7% usage of chemoprophylaxis, the
net cost for the public health system would be € 328’300
and a reduction of 278 malaria cases (from 624 to 346), if
the 80% reimbursement of the cheapest malaria chemo-
prophylaxis would be introduced (Table 4).
Cost-effectiveness analysis of the 80% reimbursement
strategy
The main medical effectiveness of the model is given in
the number of malaria cases prevented and secondarily
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by the number of malaria related deaths prevented. The
results are summarized in Table 3 and 4.
The 80% reimbursement strategy is dominant (i.e. cost
saving and more effective than the current situation) in
both situations of 55% and 68.7% recourse to malaria
chemoprophylaxis. For the 82.4% recourse situation the
incremental cost per additional malaria case prevented
is € 2’302 and for prevention of one malaria related
death € 191’833.
These results underline the high influence of the cur-
rent situation on the recourse to malaria chemoprophy-
laxis in our model.
The sensitivity analysis
The one-way sensitivity analysis on the cost of the 80%
reimbursement strategy shows the highest sensitivity for
the following variables: probability of recourse to
malaria chemoprophylaxis, probability of contracting
malaria without malaria chemoprophylaxis, cost of
mefloquine regimen, the decrease in the number of tra-
vellers without malaria chemoprophylaxis in the reim-
bursement strategy. All other variables have a minor
effect on the incremental cost effectiveness ratio. The
effects on the incremental cost effectiveness ratio per
averted malaria case are presented in Table 5 for these
Table 3 Relative cost and effects of the cost effectiveness analysis shown for the three different estimates on current
recourse to malaria chemoprophylaxis
Cost-effectiviness analysis with the
three different estimated ‘recourse
to malaria chemoprophylaxis’
55% 68.70% 82.40%
Current
situation of no
reimbursement
80%
reimbursement
strategy
Current
situation of no
reimbursement
80%
reimbursement
strategy
Current
situation of no
reimbursement
80%
reimbursement
strategy
Cost per journey (€)
(95% CI)
65.45
(47.88 - 86.03)
50.94
(41.25 - 62.36)
50.05
(36.76 - 65.50)
45.36
(37.38 - 54.96)
36.64
(25.49 - 45.46)
39.78
(33.42 - 47.74)
Effect per journey (%) (95% CI) =
probabilty of contracting malaria
0.01196
(0.00861 -
0.01587)
0.00625 (0.00445
-0.00836)
0.00891
(0.00640 -
0.01184)
0.00494 (0.00348
- 0.00669)
0.00586
(0.00417 -
0.00786)
0.00363 (0.00249
- 0.00506)
Cost Effectiveness ratio (€)
Per case of malaria prevented - 8’151 - 9’186 - 10’969
Per malaria related death
prevented
- 679’250 - 765’490 - 914’045
Incremental cost (€) of 80%
reimbursement strategy
Per additional malaria case
prevented
Reference
strategy
dominant Reference
strategy
dominant Reference
strategy
2’302
Per additional malaria related
death prevented
Reference
strategy
dominant Reference
strategy
dominant Reference
strategy
191’833
Table 4 Absolute cost and effects calculated for an estimated 70’000 travellers from Switzerland to West Africa for the
three different estimates on current recourse to malaria chemoprophylaxis
Cost-effectiviness analysis with the
three different estimated ‘recourse
to malaria chemoprophylaxis’
55% 68.70% 82.40%
Current
situation of no
reimbursement
80%
reimbursement
strategy
Current
situation of no
reimbursement
80%
reimbursement
strategy
Current
situation of no
reimbursement
80%
reimbursement
strategy
Estimated number of travellers from
Switzerland to West Africa
70’000
Cost per year (€) likliest 4’581’654 3’565’716 3’503’346 3’175’326 2’425’038 2’784’936
Effect per year likliest
Malaria cases 837 438 624 346 410 254
Malaria-related deaths 10 5 7 4 5 3
Effectiveness of 80% reimbursement
strategy
Malaria cases prevented - 399 - 278 - 156
Malaria-related deaths prevented - 5 - 3 - 2
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parameters and the ICER of reimbursing atovaquone/
proguanil or doxycycline instead of mefloquine are
shown.
The probabilistic sensitivity analysis (Figure 2) resulted
in a 95% probability of being dominant in the situation
of 68.7% recourse to malaria chemoprophylaxis based
on data from Table 2.
Discussion
The cost-effectiveness analysis in this study suggests that
an 80% reimbursement of the cheapest chemoprophy-
laxis regimen in Swiss travellers to West Africa could
lead to a substantial reduction in malaria cases and be
cost effective to the Swiss Health System. The evaluation
of the three scenarios on recourse to malaria
chemoprophylaxis showed that the results are highly
dependent on the input variable ‘use of or recourse to
malaria chemoprophylaxis’ for which only inaccurate
data exist. A low use of chemoprophylaxis as seen in
immigrant travellers could make this strategy highly
interesting for the decision makers.
Strength and weaknesses
This study gives a good overview about imported
malaria from a high risk area in the form of a model
with the all important variables in it. We tried to
include as many direct factors as possible in the model
while also keeping it as simple as possible. It has to be
remembered that we conducted a cost effectiveness ana-
lysis with the comparison between the current situation
of no reimbursement and a strategy of 80% reimburse-
ment of the cheapest malaria chemoprophylaxis. The
model is robust and changes in input data such as
underestimations of cost of treating malaria cases or
hospitalization rate will not unduly influence the out-
come. The model can also easily be adapted to more
precise input factors or to other population group with
a different situation on imported malaria.
A weakness of the analysis is the lack of exact data on
the input factor ‘use of or recourse to malaria chemopro-
phylaxis’ and this factor has a major impact on the ICER
(incremental cost effectiveness ratio). There were no spe-
cific data on chemoprophylaxis use available for Swiss
residents. So we used an estimation based on European
residents derived from the data of the airport study
which was conducted in nine different airports in Europe
with passengers residing in Europe and boarding a flight
to West Africa [12]. This information is, however, not
representative, because targeted destinations and flights
were pre-selected for practical reasons, the study partici-
pation was on voluntarily basis and unprepared travellers
were probably less likely to participate. This meant a bias
in favour of those using chemoprophylaxis and a result-
ing overestimation of recourse to malaria chemoprophy-
laxis. The three studies from France, which Pistone et al.
analyzed for travellers to West Africa, might underesti-
mate the recourse to malaria chemoprophylaxis for Swiss
travellers [13-15]. The proportion of immigrants from
West Africa living in France is higher than in Switzer-
land. Several studies have shown that visiting friends and
relatives (VFR) are at increased risk of acquiring malaria
[5,7]. One of the reasons is the lower recourse to malaria
chemoprophylaxis.
The incidence of malaria in travellers, who stopped
taking malaria chemoprophylaxis (withdrawals), was
assumed to be the same as travellers without malaria
chemoprophylaxis. But they could still have a limited
protection from the taken malaria chemoprophylaxis
and it would overestimate the incidence of malaria.
Table 5 One way sensitivity analysis on the incremental
cost effectiveness ratio (ICER) for selected input factors
with the highest influence on the model shown for a
current usage on malaria chemoprophylaxis of 68.7%
Scenario €/’malaria cases
averted’*
Current probability of recourse to malaria
chemoprophylaxis
Very low (40%) dominant
Low (55%) dominant
High (82.4%) 2’302
Probability of contracting malaria without malaria
chemoprophylaxis for a two week stay
Extremly low (= 0.4%) 19’899
Very low (= 0.9%) 5’922
Low, (= 1.2%) 3’126
A bit low, -30% (= 1.7%) 548
High, +30% (= 3.1%) dominant
Cost of the mefloquine drug
Low, -30% (= € 15.54) dominant
High, +30% (= € 28.86) dominant
Decrease of ‘non-malaria chemoprophylaxis-users’
due to the 80% reimbursement
Low, -30% (40%) 126
High, +30% (74%) dominant
Reimbursement of the more expansive drugs
Doxycycline (€ 30.23) dominant
80% reimbursement of all three drugs 4’968
Percentage of reimbursement of the cheapest
malaria chemoprophylaxis
Very low (60%) dominant
Low (70%) dominant
High (90%) dominant
Very High (100%) dominant
*the incremental cost effectiveness ratio (ICER) per averted malaria case
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In our model we considered only the three recom-
mended chemoprophylactic agents for West Africa from
the Swiss Federal Office of Public Health (FOPH):
mefloquine, atovaquone/proguanil and doxycyline.
Others, like chloroquine, which has a partial prophylac-
tic effectiveness, were excluded from the model. This
could lead to an overestimation of the incidence of
malaria cases.
The increase in malaria chemoprophylaxis users for
our 80% reimbursement strategy was assumed based on
the study of Pistone et al. [11]. We made a conservative
assumption and took the same factor (57%) for the
increase of malaria chemoprophylaxis-users as Pistone
et al. in their 65% reimbursement strategy. This would
possibly underestimate the ICER. But it has to be
remembered that travellers seeking travel advice in a
health clinic still have to pay for the visit by themselves.
The number of travellers to West Africa was esti-
mated using air transportation statistics, but it included
only travellers with a flight ticket where the final desti-
nation was an airport in West Africa. Travellers flying
to a destination in West Africa via secondary routes are
not registered. This fact has no influence on the incre-
mental cost and effectiveness as well as the ICER, but
they have a main impact on the absolute number of
malaria cases, malaria related deaths and their associated
cost for the Swiss health system. This makes the valida-
tion of our model more difficult. The results of the
model with the estimated annual number of travellers of
70’000 overestimated in all three situation of recourse to
malaria chemoprophylaxis the number of malaria cases
reported at the Swiss Federal Office of Public Health
(FOPH). The origin of the malaria acquisition is not
known for every reported malaria case and may under-
estimate the true number of malaria cases from West
Africa. Furthermore, the model does not include malaria
cases that are treated outside of Switzerland.
The 80% reimbursement strategy of only the cheapest
malaria chemoprophylaxis (mefloquine) makes the pro-
portional prices of the three recommended malaria che-
moprophylaxis agents very diverse: for a two week stay
the price reduction for mefloquine would be 80%, for
doxycyline 59% and for atovaquone/proguanil 21%.
These percentages change with chosen brand names
and travel duration. In Switzerland, broken packs are
not dispensed in this situation. This idea of giving a
voucher for malaria chemoprophylactic medication
equivalent to 80% of the cost of the cheapest anti-
malaria regimen is a new and an innovative approach to
increase the recourse to prophylactic drugs. Mefloquine
has the advantage of wide applicability (including small
children, pregnant women, long-term travellers) and is
comparable with other malaria chemoprophylaxis in its
prophylactic effectiveness and frequency of severe
adverse events but is associated with a high incidence of
non-serious adverse events, particularly in women, that
may impact on well being [9]. Contraindications for
mefloquine are: active depression, a recent history of
depression, generalized anxiety disorder, psychosis, or
schizophrenia or other major psychiatric disorders, or
with a history of convulsions. The similar prophylactic
efficacy of the three regimens, differing mainly in their
contraindications, makes this 80% reimbursement of the
cheapest malaria chemoprophylactic agents a reasonable
Figure 2 Incremental Cost Effectiveness (ICE) scatterplot: probabilistic sensitivity analysis shown for the situation of 68.7% recourse to
malaria chemoprophylaxis.
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proposition. The realization of the 80% reimbursement
strategy of the cheapest malaria chemoprophylaxis,
mefloquine, for a journey to West Africa could be made
by delivering a voucher for the given travel duration
approved by a valid individual ticket for a destination in
West Africa.
Comparison with other studies
In the literature, one other cost-effectiveness analysis
has been conducted from the perspective of the French
health system for travellers to Sub-Saharan Africa and
the results showed that the incremental cost of their
65% reimbursement strategy has a positive cost-effec-
tiveness impact [11]. Two older studies analyzed cost
minimization in use of malaria chemoprophylaxis in tra-
vellers and concluded that malaria chemoprophylaxis is
cost-effective from the perspective from the British
health care system and also from the German and Swiss
systems respectively [25,26].
Meaning of the study
In most economic analyses, where two strategies or
more are compared, the incremental cost effectiveness
ratio, ICER, is given in life years gained or QALY (qual-
ity adjusted life years). This study used averted malaria
cases as ICER and not QALYs. The National Institute
for Health and Clinical Excellence (NICE), is a specific
health authority of the National Health Service (NHS) in
Britain which gives guidelines for appropriate treatment
regimens for different diseases. NICE considers a treat-
ment intervention with a threshold of € 22’962 to
€ 34’443 (£20’00 to £30’000) per QALY to be cost effec-
tive. If our study results were expressed in terms of
QALYs, the theoretical calculations are as follow:
The average age at death due to malaria in Switzer-
land is 51.3 years [4]. The life expectancy in Switzerland
is around 83 years [27]. That would lead to 31.7 life
years lost. If we assumed that the average quality of
these 31.7 life years is 0.8 it would be 25 QALY. The
costs of the 80% reimbursement for one malaria related
death averted is € 7673 (€ 191’833 divided by
25 QALY), using the study study assumption that 82.4%
of travellers to West Africa use chemoprophylaxis, The
80% reimbursement is considered cost effective accord-
ing to the NICE guidelines.
Implications for research and policy
This study attempts to provide economic data on the
costs of malaria prevention and the expenses associated
with imported malaria in industrialized countries. This
analysis is based on traveller data. Travellers to West
Africa are not homogeneous but comprise tourist, busi-
ness travellers and increasing numbers of “visiting
friends and relative” travellers. Currently in Switzerland
the main burden of malaria is borne by this last group
and future research can possibility focus on this group
in economic evaluations as some studies have shown
that chemoprophylaxis use in this group falls far short
of the 55% recourse to chemoprophylaxis assumed in
this analysis [7]. Other countries with large migrant
populations can also consider such economic evalua-
tions for malaria and travel-related illness.
Conclusion
An 80% reimbursement of the cheapest malaria chemo-
prophylaxis or a voucher of the equivalent amount of
money for an alternative chemoprophylactic regimen for
travellers from Switzerland to West Africa is expected
to be highly effective in terms of malaria cases averted
and is cost-effective for the Swiss health system. In cer-
tain groups of high risk travellers, such as VFR travel-
lers, chemoprophylaxis use is much lower and here an
80% reimbursement would be highly cost effective.
These data are relevant to discussions about the cost
effectiveness of malaria chemoprophylaxis reimburse-
ment for vulnerable groups such as those visting friends
and relatives.
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